Semaglutida
GLP-1 receptor agonist
Long-acting GLP-1 agonist for glycemic and weight control.
Back to technical sheets- Class
- GLP-1 receptor agonist
- Also known as
- Marketed under various brands (e.g. Ozempic®, Wegovy®, Rybelsus®)
Mechanism of action
Selective GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and increases central satiety. Its modification (an amino-acid substitution plus a fatty-acid chain that binds albumin) gives it a ~1-week half-life.
Evidence
Solid clinical evidence: regulatory approval and large trial programs (SUSTAIN, STEP, SELECT), including cardiovascular outcomes.
Studied uses
- Type 2 diabetes mellitus (glycemic control)
- Obesity and overweight with comorbidity
- Cardiovascular risk reduction in specific populations
Safety considerations
- Frequent gastrointestinal effects (nausea, vomiting, diarrhea)
- Medullary thyroid carcinoma / MEN2 warning (contraindicated with personal or family history)
- Caution with pancreatitis; do not use in pregnancy
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Presentation
- Polvo liofilizado en vial sellado
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.